JOURNAL ARTICLE
RESEARCH SUPPORT, NON-U.S. GOV'T
Add like
Add dislike
Add to saved papers

Aminophylline reduces cerebral blood flow in stable, preterm infants without affecting the visual evoked potential.

The effect of intravenous aminophylline (10 mg/kg) on cerebral blood flow (CBF) and single flash visual evoked potential (VEP) was investigated in 16 preterm infants (range 25-34 weeks). All infants were weaned from mechanical ventilation and had normal brain ultrasonograms. CBF, PaO2, PaCO2, mean arterial blood pressure and VEP were recorded before, immediately after and 1 h after the administration of aminophylline. When intra-individual changes in PaCO2 were taken into account, mean CBF was 5.5% lower than the baseline value immediately after administration of aminophylline, but this was not statistically significant (P = 0.14). After 1 h, however, CBF had decreased by a mean of 13.8% (P = 0.0003). The cerebral function estimated from VEP was not influenced by aminophylline since the VEP configuration and the VEP parameters remained constant throughout the study. It is concluded that aminophylline reduces cerebral blood flow in stable, preterm infants and apparently without inducing adverse effects on cerebral function.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app